Survivin expression impacts prognostically on NSCLC but not SCLC

Lung Cancer

Volumn 79, Issue 2, 2013, Pages 180-186

  Rosato, Antonio ^a,b   Menin, Chiara ^b   Boldrin, Daniela ^b   Santa, Silvia Dalla ^b   Bonaldi, Laura ^b   Scaini, Maria Chiara ^a   Del Bianco, Paola ^b   Zardo, Davide ^a   Fassan, Matteo ^a   Cappellesso, Rocco ^a   Fassina, Ambrogio ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

DNA sequencing; FISH; Immunohistochemistry; NSCLC; Real time RT PCR; SCLC; Survivin

Indexed keywords

MESSENGER RNA; SURVIVIN;

ALLELE; ARTICLE; CANCER PROGNOSIS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASM; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION; GENE SEQUENCE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; LUNG PARENCHYMA; LUNG SMALL CELL CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM;

CARCINOMA, NON-SMALL-CELL LUNG; CELL NUCLEUS; CYTOPLASM; FEMALE; GENE EXPRESSION; GENOTYPE; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; KAPLAN-MEIER ESTIMATE; LUNG; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROMOTER REGIONS, GENETIC; RNA, MESSENGER; ROC CURVE; SMALL CELL LUNG CARCINOMA;

EID: 84872142746     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2012.11.004     Document Type: Article

References (52)

1. Fassina A., Corradin M., Zardo D., Cappellesso R., Corbetti F., Fassan M. Role and accuracy of rapid on-site evaluation of CT-guided fine needle aspiration cytology of lung nodules. Cytopathology 2011, 22:306-312.
2. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
3. Jemal A., Center M.M., DeSantis C., Ward E.M. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 2010, 19:1893-1907.
4. Tanoue L.T., Detterbeck F.C. New TNM classification for non-small-cell lung cancer. Expert Rev Anticancer Ther 2009, 9:413-423.
5. Travis W.D., Rekhtman N. Pathological diagnosis and classification of lung cancer in small biopsies and cytology: strategic management of tissue for molecular testing. Semin Respir Crit Care Med 2011, 32:22-31.
6. Tomaszek S.C., Wigle D.A. Surgical management of lung cancer. Semin Respir Crit Care Med 2011, 32:69-77.
7. William W.N., Glisson B. Novel strategies for the treatment of small-cell lung carcinoma. Nat Rev Clin Oncol 2011, 8:611-619.
8. Ramalingam S.S., Owonikoko T.K., Khuri F.R. Lung cancer: new biological insights and recent therapeutic advances. CA Cancer J Clin 2011, 61:91-112.
9. Fassina A., Cappellesso R., Fassan M. Classification of non-small cell lung carcinoma in transthoracic needle specimens using microRNA expression profiling. Chest 2011, 140:1305-1311.
10. Altieri D.C. Survivin cancer networks and pathway-directed drug discovery. Nat Rev Cancer 2008, 8:61-70.
11. Altieri D.C. Survivin and IAP proteins in cell-death mechanisms. Biochem J 2010, 430:199-205.
12. Cheung C.H., Cheng L., Chang K.Y., Chen H.H., Chang J.Y. Investigations of survivin: the past, present and future. Front Biosci 2011, 16:952-961.
13. Kelly R.J., Lopez-Chavez A., Citrin D., Janik J.E., Morris J.C. Impacting tumor cell-fate by targeting the inhibitor of apoptosis protein survivin. Mol Cancer 2011, 10:10-35.
14. Akyurek N., Memis L., Ekinci O., Kokturk N., Ozturk C. Survivin expression in pre-invasive lesions and non-small cell lung carcinoma. Virchows Arch 2006, 449:164-170.
15. Bria E., Visca P., Novelli F., Casini B., Diodoro M.G., Perrone-Donnorso R., et al. Nuclear and cytoplasmic cellular distribution of survivin as survival predictor in resected non-small-cell lung cancer. Eur J Surg Oncol 2008, 34:593-598.
16. Dai C.H., Li J., Shi S.B., Yu L.C., Ge L.P., Chen P. Survivin and Smac gene expressions but not livin are predictors of prognosis in non-small cell lung cancer patients treated with adjuvant chemotherapy following surgery. Jpn J Clin Oncol 2010, 40:327-335.
17. Falleni M., Pellegrini C., Marchetti A., Oprandi B., Buttitta F., Barassi F., et al. Survivin gene expression in early-stage non-small cell lung cancer. J Pathol 2003, 200:620-626.
18. Fan C.F., Xu H.T., Lin X.Y., Yu J.H., Wang E.H. A multiple marker analysis of apoptosis-associated protein expression in non-small cell lung cancer in a Chinese population. Folia Histochem Cytobiol 2011, 49:231-239.
19. Fan J., Wang L., Jiang G.N., He W.X., Ding J.A. The role of survivin on overall survival of non-small cell lung cancer, a meta-analysis of published literatures. Lung Cancer 2008, 61:91-96.
20. Karczmarek-Borowska B., Filip A., Wojcierowski J., Smolen A., Pilecka I., Jablonka A. Survivin antiapoptotic gene expression as a prognostic factor in non-small cell lung cancer: in situ hybridization study. Folia Histochem Cytobiol 2005, 43:237-242.
21. Oshita F., Ito H., Ikehara M., Ohgane N., Hamanaka N., Nakayama H., et al. Prognostic impact of survivin, cyclin D1, integrin beta1, and VEGF in patients with small adenocarcinoma of stage I lung cancer. Am J Clin Oncol 2004, 27:425-428.
22. Shinohara E.T., Gonzalez A., Massion P.P., Chen H., Li M., Freyer A.S., et al. Nuclear survivin predicts recurrence and poor survival in patients with resected nonsmall cell lung carcinoma. Cancer 2005, 103:1685-1692.
23. Ulukus E.C., Kargi H.A., Sis B., Lebe B., Oztop I., Akkoclu A., et al. Survivin expression in non-small-cell lung carcinomas: correlation with apoptosis and other apoptosis-related proteins, clinicopathologic prognostic factors and prognosis. Appl Immunohistochem Mol Morphol 2007, 15:31-37.
24. Vischioni B., van der Valk P., Span S.W., Kruyt F.A., Rodriguez J.A., Giaccone G. Nuclear localization of survivin is a positive prognostic factor for survival in advanced non-small-cell lung cancer. Ann Oncol 2004, 15:1654-1660.
25. Warnecke-Eberz U., Baldus S.E., Bollschweiler E., Hoelscher A.H., Metzger R. Up-regulation of survivin mRNA might be a marker for non-invasive detection of non-small cell lung cancer rather than for prognosis. Anticancer Res 2008, 28:1525-1529.
26. Yamashita S., Chujo M., Miyawaki M., Tokuishi K., Anami K., Yamamoto S., et al. Combination of p53AIP1 and survivin expression is a powerful prognostic marker in non-small cell lung cancer. J Exp Clin Cancer Res 2009, 28:22.
27. Srivastava K., Srivastava A., Mittal B. Survivin promoter -31G/C (rs9904341) polymorphism and cancer susceptibility: a meta-analysis. Mol Biol Rep 2011, 39:1509-1516.
28. Jang J.S., Kim K.M., Kang K.H., Choi J.E., Lee W.K., Kim C.H., et al. Polymorphisms in the survivin gene and the risk of lung cancer. Lung Cancer 2008, 60:31-39.
29. Chen P., Li J., Ge L.P., Dai C.H., Li X.Q. Prognostic value of survivin, X-linked inhibitor of apoptosis protein and second mitochondria-derived activator of caspases expression in advanced non-small-cell lung cancer patients. Respirology 2010, 15:501-509.
30. Rosato A., Pivetta M., Parenti A., Iaderosa G.A., Zoso A., Milan G., et al. Survivin in esophageal cancer: an accurate prognostic marker for squamous cell carcinoma but not adenocarcinoma. Int J Cancer 2006, 119:1717-1722.
31. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-408.
32. Bonanno L., Schiavon M., Nardo G., Bertorelle R., Bonaldi L., Galligioni A., et al. Prognostic and predictive implications of EGFR mutations, EGFR copy number and KRAS mutations in advanced stage lung adenocarcinoma. Anticancer Res 2010, 30:5121-5128.
33. Borbely A.A., Murvai M., Szarka K., Konya J., Gergely L., Hernadi Z., et al. Survivin promoter polymorphism and cervical carcinogenesis. J Clin Pathol 2007, 60:303-306.
34. Swets J.A. Measuring the accuracy of diagnostic systems. Science 1988, 240:1285-1293.
35. Contal C., O'Quigley J. An application of changepoint methods in studying the effect of age on survival in breast cancer. Comput Stat Data Anal 1999, 30:253-270.
36. Beer D.G., Kardia S.L., Huang C.C., Giordano T.J., Levin A.M., Misek D.E., et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 2002, 8:816-824.
37. Garber M.E., Troyanskaya O.G., Schluens K., Petersen S., Thaesler Z., Pacyna-Gengelbach M., et al. Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci USA 2001, 98:13784-13789.
38. Landi M.T., Dracheva T., Rotunno M., Figueroa J.D., Liu H., Dasgupta A., et al. Gene expression signature of cigarette smoking and its role in lung adenocarcinoma development and survival. PLoS ONE 2008, 3:e1651.
39. Su L.J., Chang C.W., Wu Y.C., Chen K.C., Lin C.J., Liang S.C., et al. Selection of DDX5 as a novel internal control for Q-RT-PCR from microarray data using a block bootstrap re-sampling scheme. BMC Genomics 2007, 8:140.
40. Wachi S., Yoneda K., Wu R. Interactome-transcriptome analysis reveals the high centrality of genes differentially expressed in lung cancer tissues. Bioinformatics 2005, 21:4205-4208.
41. Rohrbeck A., Neukirchen J., Rosskopf M., Pardillos G.G., Geddert H., Schwalen A., et al. Gene expression profiling for molecular distinction and characterization of laser captured primary lung cancers. J Transl Med 2008, 6:69.
42. Beroukhim R., Mermel C.H., Porter D., Wei G., Raychaudhuri S., Donovan J., et al. The landscape of somatic copy-number alteration across human cancers. Nature 2010, 463:899-905.
43. Caldarella A., Crocetti E., Comin C.E., Janni A., Pegna A.L., Paci E. Prognostic variability among nonsmall cell lung cancer patients with pathologic N1 lymph node involvement. Epidemiological figures with strong clinical implications. Cancer 2006, 107:793-798.
44. Nakamura H., Ando K., Shinmyo T., Morita K., Mochizuki A., Kurimoto N., et al. Female gender is an independent prognostic factor in non-small-cell lung cancer: a meta-analysis. Ann Thorac Cardiovasc Surg 2011, 17:469-480.
45. Zhang L.Q., Wang J., Jiang F., Xu L., Liu F.Y., Yin R. Prognostic value of survivin in patients with non-small cell lung carcinoma: a systematic review with meta-analysis. PLoS ONE 2012, 7:e34100.
46. Belyanskaya L.L., Hopkins-Donaldson S., Kurtz S., Simoes-Wust A.P., Yousefi S., Simon H.U., et al. Cisplatin activates Akt in small cell lung cancer cells and attenuates apoptosis by survivin upregulation. Int J Cancer 2005, 117:755-763.
47. Halasova E., Adamkov M., Matakova T., Kavcova E., Poliacek I., Singliar A. Lung cancer incidence and survival in chromium exposed individuals with respect to expression of anti-apoptotic protein survivin and tumor suppressor P53 protein. Eur J Med Res 2010, 15(Suppl. 2):55-59.
48. Lu B., Gonzalez A., Massion P.P., Shyr Y., Shaktour B., Carbone D.P., et al. Nuclear survivin as a biomarker for non-small-cell lung cancer. Br J Cancer 2004, 91:537-540.
49. Jacob N.K., Cooley J.V., Shirai K., Chakravarti A. Survivin splice variants are not essential for mitotic progression or inhibition of apoptosis induced by doxorubicin and radiation. Oncol Targets Ther 2012, 5:7-20.
50. Islam A., Kageyama H., Takada N., Kawamoto T., Takayasu H., Isogai E., et al. High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene 2000, 19:617-623.
51. Xu Y., Fang F., Ludewig G., Jones G., Jones D. A mutation found in the promoter region of the human survivin gene is correlated to overexpression of survivin in cancer cells. DNA Cell Biol 2004, 23:419-429.
52. Antonacopoulou A.G., Floratou K., Bravou V., Kottorou A., Dimitrakopoulos F.I., Marousi S., et al. The survivin -31 SNP in human colorectal cancer correlates with survivin splice variant expression and improved overall survival. Anal Cell Pathol (Amst) 2010, 33:177-189.